Quick Answer
Alaunos Therapeutics, Inc. reported R&D Expense of $1.36 million for fiscal year 2025.
Alaunos Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $1.36M | +276.5% |
| 2024 | $362.0K | -97.8% |
| 2023 | $16.28M | -34.9% |
| 2022 | $25.02M | -49.6% |
| 2021 | $49.64M | -5.8% |
| 2020 | $52.70M | +37.5% |
| 2019 | $38.33M | +12.3% |
| 2018 | $34.13M | -24.3% |
| 2017 | $45.08M | -71.4% |
| 2016 | $157.79M | +47.8% |
| 2015 | $106.78M | +226.5% |
| 2014 | $32.71M | -23.7% |
| 2013 | $42.85M | -48.6% |
| 2012 | $83.45M | +46.2% |
| 2011 | $57.08M | +226.2% |
| 2010 | $17.50M | +284.1% |
| 2009 | $4.56M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $469.0K | +228.0% | +153.5% |
| June 30, 2025 | $185.0K | +2.8% | -46.7% |
| March 31, 2025 | $347.0K | +175.4% | +142.7% |
| September 30, 2024 | $143.0K | -96.1% | -20.6% |
| June 30, 2024 | $180.0K | -96.5% | +42.9% |
| March 31, 2024 | $126.0K | -98.1% | -96.6% |
| September 30, 2023 | $3.66M | -53.7% | -29.5% |
| June 30, 2023 | $5.19M | -12.6% | -20.3% |
- Alaunos Therapeutics, Inc. showed an increase of +276.5% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2025 period, Alaunos Therapeutics, Inc.’s r&d expense has declined by 70.1% (from $4.56 million to $1.36 million).
- The most recent figure is from Alaunos Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: